Literature DB >> 25688404

NUT midline carcinoma.

Christopher French1.   

Abstract

NUT midline carcinoma, a squamous cell carcinoma, is one of the most aggressive human cancers, and there is a desperate need for effective therapies for patients with this disease. Will the new bromodomain and extra terminal (BET) inhibitors prove to be one such treatment for this rare and enigmatic cancer?

Entities:  

Mesh：

Substances：

Year:  2014        PMID： 25688404     DOI： 10.1038/nrc3659

Source DB:  PubMed          Journal:  Nat Rev Cancer        ISSN： 1474-175X            Impact factor:   60.716


  7 in total

1.  Oncogenesis by sequestration of CBP/p300 in transcriptionally inactive hyperacetylated chromatin domains.

Authors:  Nicolas Reynoird; Brian E Schwartz; Manuela Delvecchio; Karin Sadoul; David Meyers; Chandrani Mukherjee; Cécile Caron; Hiroshi Kimura; Sophie Rousseaux; Philip A Cole; Daniel Panne; Christopher A French; Saadi Khochbin
Journal:  EMBO J       Date:  2010-07-30       Impact factor: 11.598

2.  Differentiation of NUT midline carcinoma by epigenomic reprogramming.

Authors:  Brian E Schwartz; Matthias D Hofer; Madeleine E Lemieux; Daniel E Bauer; Michael J Cameron; Nathan H West; Elin S Agoston; Nicolas Reynoird; Saadi Khochbin; Tan A Ince; Amanda Christie; Katherine A Janeway; Sara O Vargas; Antonio R Perez-Atayde; Jon C Aster; Stephen E Sallan; Andrew L Kung; James E Bradner; Christopher A French
Journal:  Cancer Res       Date:  2011-03-29       Impact factor: 12.701

3.  Clinicopathologic features and long-term outcomes of NUT midline carcinoma.

Authors:  Daniel E Bauer; Chelsey M Mitchell; Kelly M Strait; Christopher S Lathan; Edward B Stelow; Sonja C Lüer; Somala Muhammed; Andrew G Evans; Lynette M Sholl; Juan Rosai; Eugenia Giraldi; Richard P Oakley; Carlos Rodriguez-Galindo; Wendy B London; Stephen E Sallan; James E Bradner; Christopher A French
Journal:  Clin Cancer Res       Date:  2012-08-15       Impact factor: 12.531

4.  MYC, a downstream target of BRD-NUT, is necessary and sufficient for the blockade of differentiation in NUT midline carcinoma.

Authors:  Adlai R Grayson; Erica M Walsh; Michael J Cameron; Jernej Godec; Todd Ashworth; Jessica M Ambrose; Alexandra B Aserlind; Hongfang Wang; Gerard Evan; Michael J Kluk; James E Bradner; Jon C Aster; Christopher A French
Journal:  Oncogene       Date:  2013-04-22       Impact factor: 9.867

5.  Diagnosis of NUT midline carcinoma using a NUT-specific monoclonal antibody.

Authors:  Herbert Haack; Laura A Johnson; Christopher J Fry; Katherine Crosby; Roberto D Polakiewicz; Edward B Stelow; Seung-Mo Hong; Brian E Schwartz; Michael J Cameron; Mark A Rubin; Martin C Chang; Jon C Aster; Christopher A French
Journal:  Am J Surg Pathol       Date:  2009-07       Impact factor: 6.394

6.  BRD-NUT oncoproteins: a family of closely related nuclear proteins that block epithelial differentiation and maintain the growth of carcinoma cells.

Authors:  C A French; C L Ramirez; J Kolmakova; T T Hickman; M J Cameron; M E Thyne; J L Kutok; J A Toretsky; A K Tadavarthy; U R Kees; J A Fletcher; J C Aster
Journal:  Oncogene       Date:  2007-10-15       Impact factor: 9.867

7.  Selective inhibition of BET bromodomains.

Authors:  Panagis Filippakopoulos; Jun Qi; Sarah Picaud; Yao Shen; William B Smith; Oleg Fedorov; Elizabeth M Morse; Tracey Keates; Tyler T Hickman; Ildiko Felletar; Martin Philpott; Shonagh Munro; Michael R McKeown; Yuchuan Wang; Amanda L Christie; Nathan West; Michael J Cameron; Brian Schwartz; Tom D Heightman; Nicholas La Thangue; Christopher A French; Olaf Wiest; Andrew L Kung; Stefan Knapp; James E Bradner
Journal:  Nature       Date:  2010-09-24       Impact factor: 49.962
  7 in total
  47 in total

Review 1.  The 2015 World Health Organization Classification of Tumors of the Thymus: Continuity and Changes.

Authors:  Alexander Marx; John K C Chan; Jean-Michel Coindre; Frank Detterbeck; Nicolas Girard; Nancy L Harris; Elaine S Jaffe; Michael O Kurrer; Edith M Marom; Andre L Moreira; Kiyoshi Mukai; Attilio Orazi; Philipp Ströbel
Journal:  J Thorac Oncol       Date:  2015-10       Impact factor: 15.609

Review 2.  Developing Cures: Targeting Ontogenesis in Cancer.

Authors:  Victor T G Lin; Hawley C Pruitt; Rajeev S Samant; Lalita A Shevde
Journal:  Trends Cancer       Date:  2017-01-27

3.  Salivary Gland NUT Carcinoma with Prolonged Survival in Children: Case Illustration and Systematic Review of Literature.

Authors:  Huiying Wang; Vivian L Weiss; Robert D Hoffman; Ty Abel; Richard H Ho; Scott C Borinstein; Kyle Mannion; Julia A Bridge; Jennifer Black; Jiancong Liang
Journal:  Head Neck Pathol       Date:  2020-02-19

Review 4.  Genetics and prognosis of ALL in children vs adults.

Authors:  Kathryn G Roberts
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2018-11-30

5.  Ectopic protein interactions within BRD4-chromatin complexes drive oncogenic megadomain formation in NUT midline carcinoma.

Authors:  Artyom A Alekseyenko; Erica M Walsh; Barry M Zee; Tibor Pakozdi; Peter Hsi; Madeleine E Lemieux; Paola Dal Cin; Tan A Ince; Peter V Kharchenko; Mitzi I Kuroda; Christopher A French
Journal:  Proc Natl Acad Sci U S A       Date:  2017-05-08       Impact factor: 11.205

Review 6.  Update on genetically defined lung neoplasms: NUT carcinoma and thoracic SMARCA4-deficient undifferentiated tumors.

Authors:  Kyriakos Chatzopoulos; Jennifer M Boland
Journal:  Virchows Arch       Date:  2021-01-06       Impact factor: 4.064

Review 7.  Emerging molecular subtypes and therapeutic targets in B-cell precursor acute lymphoblastic leukemia.

Authors:  Jianfeng Li; Yuting Dai; Liang Wu; Ming Zhang; Wen Ouyang; Jinyan Huang; Saijuan Chen
Journal:  Front Med       Date:  2021-01-05       Impact factor: 4.592

Review 8.  How advanced are we in targeting novel subtypes of ALL?

Authors:  Charles G Mullighan
Journal:  Best Pract Res Clin Haematol       Date:  2019-10-18       Impact factor: 3.020

9.  New Brain Tumor Entities Emerge from Molecular Classification of CNS-PNETs.

Authors:  Dominik Sturm; Brent A Orr; Umut H Toprak; Volker Hovestadt; David T W Jones; David Capper; Martin Sill; Ivo Buchhalter; Paul A Northcott; Irina Leis; Marina Ryzhova; Christian Koelsche; Elke Pfaff; Sariah J Allen; Gnanaprakash Balasubramanian; Barbara C Worst; Kristian W Pajtler; Sebastian Brabetz; Pascal D Johann; Felix Sahm; Jüri Reimand; Alan Mackay; Diana M Carvalho; Marc Remke; Joanna J Phillips; Arie Perry; Cynthia Cowdrey; Rachid Drissi; Maryam Fouladi; Felice Giangaspero; Maria Łastowska; Wiesława Grajkowska; Wolfram Scheurlen; Torsten Pietsch; Christian Hagel; Johannes Gojo; Daniela Lötsch; Walter Berger; Irene Slavc; Christine Haberler; Anne Jouvet; Stefan Holm; Silvia Hofer; Marco Prinz; Catherine Keohane; Iris Fried; Christian Mawrin; David Scheie; Bret C Mobley; Matthew J Schniederjan; Mariarita Santi; Anna M Buccoliero; Sonika Dahiya; Christof M Kramm; André O von Bueren; Katja von Hoff; Stefan Rutkowski; Christel Herold-Mende; Michael C Frühwald; Till Milde; Martin Hasselblatt; Pieter Wesseling; Jochen Rößler; Ulrich Schüller; Martin Ebinger; Jens Schittenhelm; Stephan Frank; Rainer Grobholz; Istvan Vajtai; Volkmar Hans; Reinhard Schneppenheim; Karel Zitterbart; V Peter Collins; Eleonora Aronica; Pascale Varlet; Stephanie Puget; Christelle Dufour; Jacques Grill; Dominique Figarella-Branger; Marietta Wolter; Martin U Schuhmann; Tarek Shalaby; Michael Grotzer; Timothy van Meter; Camelia-Maria Monoranu; Jörg Felsberg; Guido Reifenberger; Matija Snuderl; Lynn Ann Forrester; Jan Koster; Rogier Versteeg; Richard Volckmann; Peter van Sluis; Stephan Wolf; Tom Mikkelsen; Amar Gajjar; Kenneth Aldape; Andrew S Moore; Michael D Taylor; Chris Jones; Nada Jabado; Matthias A Karajannis; Roland Eils; Matthias Schlesner; Peter Lichter; Andreas von Deimling; Stefan M Pfister; David W Ellison; Andrey Korshunov; Marcel Kool
Journal:  Cell       Date:  2016-02-25       Impact factor: 41.582

Review 10.  [Sinonasal tumors : News from the WHO with special reference to mesenchymal entities].

Authors:  A Agaimy; F Haller; A Hartmann
Journal:  Pathologe       Date:  2018-02       Impact factor: 1.011
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.